Skip to main content

Table 1 Biochemical parameters

From: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway

Parameters ZL
(n = 5–9)
ZDF
(n = 7)
ZDF + Zn(ASA)2
(n = 5–6)
ZL + Zn(ASA)2
(n = 6–10)
Plasma glucose (mmol/L) 11.8 ± 0.7 49.4 ± 2.8*$ 39.0 ± 3.6*#$ 11.4 ± 0.7
Plasma HDL cholesterol (mmol/L) 0.27 ± 0.01 1.96 ± 0.11*$ 1.83 ± 0.06*$ 0.28 ± 0.02
Plasma total cholesterol (mmol/L) 2.56 ± 0.13 8.68 ± 0.89*$ 9.27 ± 0.95*$ 2.24 ± 0.14
Plasma triglycerides (mmol/L) 1.0 ± 0.2 13.5 ± 1.1*$ 17.4 ± 1.3*#$ 1.1 ± 0.1
Non-esterified fatty acid (mmol/L) 0.21 ± 0.04 0.45 ± 0.07*$ 0.49 ± 0.09*$ 0.22 ± 0.01
Serum insulin (μg/L) 0.75 ± 0.10 0.71 ± 0.08 0.70 ± 0.09 1.33 ± 0.25
Plasma GOT/AST (U/L) 64 ± 4 77 ± 12 107 ± 26 81 ± 4
  1. Biochemical profile of ZDF (Zucker diabetic fatty) and Zucker Lean (nondiabetic) rats after 24 days of treatment with either vehicle or zinc complex of acetylsalicylic acid (Zn(ASA)2). Values are mean ± SEM. * P < 0.05 vs ZL, # P < 0.05 vs ZDF, $ P < 0.05 vs ZL + Zn(ASA)2
  2. GPT indicates glutamate–oxaloacetate transaminase, AST aspartate aminotransferase, n number of animals analysed